{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:28:08Z","timestamp":1777930088516,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Das Design einer multizentrischen Phase-\u03a0-Studie zur Behandlung des Kaposi-Sarkoms (KS) bei HIV-Infizierten wird dargestellt. In dieser Studie sollen die Toxizit\u00e4t und Effektivit\u00e4t einer hochdosierten Behandlung mit alpha-interferon (20 \u00d7 106 U\/m2 s.c. t\u00e4glich) an Patienten mit fortgeschrittenem und progredientem Kaposi-Sarkom gepr\u00fcft werden. Patienten mit progredientem KS unter Interferon-Behandlung oder ein Rezidiv des KS nach Interferon-Therapie werden mit Vinblastin (4 mg\/m2 i.v., Tag 1, 8, 15) und Bleomycin (15 mg i.v., Tag 1+8) behandelt. Ergebnisse der k\u00fcrzlich aktivierten Studie liegen noch nicht vor.<\/jats:p>","DOI":"10.1159\/000216486","type":"journal-article","created":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T08:49:09Z","timestamp":1240822149000},"page":"61-62","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Advanced, Progressive Epidemic Kaposi\u2019s Sarcoma (EKS): A Phase-II Study"],"prefix":"10.1159","author":[{"given":"P.S.","family":"Mitrou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ch.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rasokat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,27]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:03:16Z","timestamp":1777680196000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216486","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}